Shandong Hile Biological Products Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.

SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Company’s products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndrome’76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.